PL3071219T3 - Sposoby leczenia zależnego od przeciwciała odrzucenia przeszczepu narządu u pacjentów za pomocą inhibitora esterazy c1 - Google Patents

Sposoby leczenia zależnego od przeciwciała odrzucenia przeszczepu narządu u pacjentów za pomocą inhibitora esterazy c1

Info

Publication number
PL3071219T3
PL3071219T3 PL14809567T PL14809567T PL3071219T3 PL 3071219 T3 PL3071219 T3 PL 3071219T3 PL 14809567 T PL14809567 T PL 14809567T PL 14809567 T PL14809567 T PL 14809567T PL 3071219 T3 PL3071219 T3 PL 3071219T3
Authority
PL
Poland
Prior art keywords
methods
organ transplant
transplant patients
esterase inhibitor
mediated rejection
Prior art date
Application number
PL14809567T
Other languages
English (en)
Inventor
Colin Broom
Marc E. Uknis
Original Assignee
Shire Viropharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52016153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3071219(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Viropharma Inc filed Critical Shire Viropharma Inc
Publication of PL3071219T3 publication Critical patent/PL3071219T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL14809567T 2013-11-22 2014-11-21 Sposoby leczenia zależnego od przeciwciała odrzucenia przeszczepu narządu u pacjentów za pomocą inhibitora esterazy c1 PL3071219T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361907550P 2013-11-22 2013-11-22
US201462029086P 2014-07-25 2014-07-25
EP14809567.2A EP3071219B1 (en) 2013-11-22 2014-11-21 Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
PCT/US2014/066784 WO2015077543A1 (en) 2013-11-22 2014-11-21 Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Publications (1)

Publication Number Publication Date
PL3071219T3 true PL3071219T3 (pl) 2019-04-30

Family

ID=52016153

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14809567T PL3071219T3 (pl) 2013-11-22 2014-11-21 Sposoby leczenia zależnego od przeciwciała odrzucenia przeszczepu narządu u pacjentów za pomocą inhibitora esterazy c1

Country Status (24)

Country Link
US (3) US9895428B2 (pl)
EP (3) EP3494988B1 (pl)
JP (5) JP6431912B2 (pl)
KR (2) KR102312817B1 (pl)
CN (2) CN111388655A (pl)
AU (2) AU2014352846B2 (pl)
BR (1) BR112016011499A2 (pl)
CA (1) CA2930964A1 (pl)
CY (1) CY1121298T1 (pl)
DK (1) DK3071219T3 (pl)
ES (1) ES2708655T3 (pl)
HR (1) HRP20190184T1 (pl)
HU (1) HUE041809T2 (pl)
LT (1) LT3071219T (pl)
ME (1) ME03318B (pl)
MX (2) MX378834B (pl)
NZ (2) NZ759187A (pl)
PL (1) PL3071219T3 (pl)
PT (1) PT3071219T (pl)
RS (1) RS58343B1 (pl)
SG (1) SG10201804326SA (pl)
SI (1) SI3071219T1 (pl)
SM (1) SMT201900042T1 (pl)
WO (1) WO2015077543A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03318B (me) * 2013-11-22 2019-10-20 Shire Viropharma Inc Postupci lečenja odbacivanja posredovanog antitelima pacijenata sa transplatiranim organom sa inhibitorom c1-esteraze
CA3075686A1 (en) 2017-09-15 2019-03-21 Cedars-Sinai Medical Center Methods for improving organ function in organ transplant patients
WO2019166572A1 (en) * 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
KR20210106521A (ko) * 2018-12-20 2021-08-30 세다르스-신나이 메디칼 센터 기관 이식체의 만성 항체 매개된 거부의 치료에서 클라자키주맙
CA3148600A1 (en) * 2019-08-08 2021-02-11 Cedars-Sinai Medical Center Methods of improving organ function
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
CN116568327A (zh) * 2020-11-20 2023-08-08 德国杰特贝林生物制品有限公司 治疗抗体介导的排斥反应的方法
CN113035369B (zh) * 2021-03-10 2021-12-03 浙江大学 一种肾移植抗感染药物剂量预测模型的构建方法
JP2024525084A (ja) 2021-07-09 2024-07-09 ファーミング・インテレクチュアル・プロパティー・ビー．ブイ． Ｃ１エステラーゼ阻害剤によるウイルス感染関連症状の治療
WO2024152030A1 (en) * 2023-01-13 2024-07-18 The Uab Research Foundation Crossmatching for porcine xenotransplantation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
DE10112617A1 (de) * 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
CA2654446C (en) 2005-06-07 2014-02-25 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
BRPI0708424A2 (pt) * 2006-03-02 2011-05-31 Alexion Pharma Inc prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento
DK2758076T3 (en) * 2011-09-24 2019-04-01 Csl Behring Gmbh COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR
WO2014135694A1 (en) * 2013-03-08 2014-09-12 Csl Behring Ag Treatment and prevention of remote ischemia-reperfusion injury
ME02865B (me) * 2013-03-15 2018-04-20 Shire Viropharma Inc C1-inh kompozicije za upotrebu u prevenciji i liječenju naslednog angioedema (hae)
ME03318B (me) 2013-11-22 2019-10-20 Shire Viropharma Inc Postupci lečenja odbacivanja posredovanog antitelima pacijenata sa transplatiranim organom sa inhibitorom c1-esteraze

Also Published As

Publication number Publication date
HRP20190184T1 (hr) 2019-03-22
AU2014352846A1 (en) 2016-06-02
HUE041809T2 (hu) 2019-05-28
KR20210125118A (ko) 2021-10-15
DK3071219T3 (en) 2019-02-25
KR102312817B1 (ko) 2021-10-13
EP3071219B1 (en) 2018-11-14
SI3071219T1 (sl) 2019-03-29
JP2016537380A (ja) 2016-12-01
EP3494988B1 (en) 2022-08-03
EP4162947A1 (en) 2023-04-12
SG10201804326SA (en) 2018-06-28
JP2019001831A (ja) 2019-01-10
NZ719724A (en) 2022-08-26
WO2015077543A1 (en) 2015-05-28
JP6620206B2 (ja) 2019-12-11
EP3494988A1 (en) 2019-06-12
JP6431912B2 (ja) 2018-11-28
AU2020200015A1 (en) 2020-01-30
ME03318B (me) 2019-10-20
AU2014352846B2 (en) 2019-10-03
AU2020200015B2 (en) 2022-03-10
MX378834B (es) 2025-03-11
MX2021000332A (es) 2021-04-13
MX2016006656A (es) 2016-09-06
CN105744949A (zh) 2016-07-06
KR20160079821A (ko) 2016-07-06
US20180104319A1 (en) 2018-04-19
CY1121298T1 (el) 2020-05-29
ES2708655T3 (es) 2019-04-10
US20150147319A1 (en) 2015-05-28
KR102384814B1 (ko) 2022-04-08
JP2021063141A (ja) 2021-04-22
SMT201900042T1 (it) 2019-02-28
EP3071219A1 (en) 2016-09-28
PT3071219T (pt) 2019-02-06
JP2019023233A (ja) 2019-02-14
US20200360495A1 (en) 2020-11-19
LT3071219T (lt) 2019-01-10
JP2022179637A (ja) 2022-12-02
US9895428B2 (en) 2018-02-20
NZ759187A (en) 2022-08-26
CA2930964A1 (en) 2015-05-28
RS58343B1 (sr) 2019-03-29
CN111388655A (zh) 2020-07-10
BR112016011499A2 (pt) 2020-10-27

Similar Documents

Publication Publication Date Title
HUE041809T2 (hu) Eljárások antitest által közvetített kilökõdés kezelésére szervbeültetéses páciensekben C1-észteráz inhibitorral
IL277633A (en) Antibodies and methods of use
IL243408A0 (en) Diagnosis and therapy of cancer involving cancer stem cells
GB201320723D0 (en) Composition and methods of treatment
SG11201601412XA (en) Compositions and methods for the treatment of presbyopia
ZA201507472B (en) Plant growth-promoting bacteria and methods of use
IL239453A0 (en) Compositions and methods for treatment of cancer using bacteria
EP2825242A4 (en) DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DEFECTS
HUE040111T2 (hu) Vegyületek és alkalmazási eljárásaik
PL2999346T3 (pl) Leczenie ziemniaków podczas magazynowania
SG10201709955PA (en) Methods of treatment and compositions with xanthine oxidase inhibitors
IL234726A0 (en) Catheter and its manufacturing method
DK3049473T3 (da) Dobbeltderivatiserede chitosannanopartikler og fremgangsmåder til fremstilling og anvendelse heraf til genoverførsel in vivo
GB201515255D0 (en) Devices and methods for purification of biological cells
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
IL245272B (en) pif-transfected cells and methods of use
PL2948137T3 (pl) Sposoby leczenia zwłóknienia i nowotworów
IL241096A0 (en) Treatment methods
PT2808305T (pt) Método de tratamento biológico de águas residuais
HRP20181181T1 (hr) Postupak obrade i liječenja lišmenioze uporabom feksinidazola
PL2999789T3 (pl) Sposób selekcjonowania inhibitorów domeny pin hdis3 oraz zastosowanie inhibitorów domeny pin hdis3 do leczenia nowotworu
GB201306975D0 (en) Stents and methods of manufacture
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment
GB201302105D0 (en) Cover Means and Method of Use Thereof